Flame Biosciences raises $100M to advance mAbs trials

By The Science Advisory Board staff writers

September 30, 2020 -- Flame Biosciences announced the completion of a $100 million common stock financing to advance clinical trials for monoclonal antibodies (mAbs).

Currently, Flame is developing mAbs that bind and neutralize interleukin-1β (IL-1β) with the intention of treating multiple diseases, specifically cancer. Clinical research shows that IL-1β is a key mediator of the chronic inflammation that causes tumor growth, and Flame's IL-1β neutralizing antibody FL-10 has the potential to treat cancer effectively, according to the company.

FL-101 will enter the clinic for proof-of-concept testing in patients with non-small cell lung cancer in the first half of 2021.

Passive vaccines with mAbs may be effective for COVID-19
Monoclonal antibodies (mAbs) isolated from the blood of recovered COVID-19 patients -- known colloquially as "convalescent plasma" -- could be potentially...
Antibody fragments may be exceptionally effective against SARS-CoV-2
An engineered antibody fragment has been developed as a highly potent neutralizer of SARS-CoV-2. For the first time, one of these tiny molecules has been...
New approach to cancer immunotherapies combines 2 mAb treatments
A new approach to increasing the effectiveness of current cancer immunotherapies combines existing therapies with new monoclonal antibodies (mAb) that...
AgilVax gets $1.2M to advance antibody-based therapy
AgilVax has been awarded a $1.2 million Fast Track Small Business Innovation Research grant by the U.S. National Cancer Institute to study a vaccine...

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter